‘Biologic’ safety of DOACs versus VKA, as no anticoagulation control is required Hepatotoxicity of COVID-19 infection and antiviral therapy in mid- and long-term evolution Renal function at discharge (creatinine clearance according to Cockcroft–Gault formula) High thrombogenicity of COVID-19: select the most effective DOAC, preferably in a twice-daily regimen Arrhythmogenicity of COVID-19: increased risk of new-onset atrial fibrillation that requires oral anticoagulation – DOACs over VKA, as DOACs facilitate sanitary education and medication adherence DOACs with a specific reversal agent may be helpful in reducing the impact of healthcare system underuse occurring during the COVID-19 pandemic

DOACs, direct oral anticoagulants; VKA, vitamin K antagonists.